Instrument Inactif

Communiqués Amyris Inc Nasdaq

Actions

US03236M1018

Chimie de spécialité

Communiqués

01/09/23	Amyris : Management Change - Form 8-K	PU
14/08/23	Amyris : Aviso aos Acionistas	PU
10/08/23	AMYRIS ANNOUNCES OPERATIONAL AND FINANCIAL RESTRUCTURING TO ADVANCE STRATEGIC TRANSFORMATION	PR
26/06/23	AMYRIS ANNOUNCES CEO TRANSITION AND GLOBAL REDUCTION IN FORCE	PR
05/06/23	AMYRIS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	AQ
05/06/23	AMYRIS INITIATES STRATEGIC TRANSFORMATION PROGRAM AND SECURES FUNDING	PR
27/05/23	Amyris : Failure to Satisfy Listing Rule - Form 8-K	PU
26/05/23	AMYRIS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
22/05/23	AMYRIS COMPLETES LICENSE FOR SUPPLY OF SUSTAINABLE SQUALENE	AQ
19/05/23	Two new partnerships for the pharmaceutical industry \| Croda	AQ
19/05/23	AMYRIS COMPLETES LICENSE FOR SUPPLY OF SUSTAINABLE SQUALENE	PR
09/05/23	AMYRIS, INC. REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS	PR
02/05/23	AMYRIS TO HOST FIRST QUARTER 2023 FINANCIAL RESULTS CONFERENCE CALL ON MAY 9	PR
24/04/23	AMYRIS REPORTS Q1 2023 REVENUE	PR
05/04/23	AMYRIS CLOSES STRATEGIC TRANSACTION WITH GIVAUDAN	PR
04/04/23	AMYRIS, INC. : Completion of Acquisition or Disposition of Assets, Other Events (form 8-K)	AQ
23/03/23	AMYRIS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	AQ
16/03/23	AMYRIS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
15/03/23	AMYRIS, INC. : Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
15/03/23	AMYRIS, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS	PR
14/03/23	AMYRIS, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)	AQ
28/02/23	AMYRIS TO HOST FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS CONFERENCE CALL ON MARCH 15, 2023	PR
24/02/23	Inside our partnership with Givaudan: expanding access to our hero ingredients and innovative technology	PU
22/02/23	AMYRIS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	AQ
22/02/23	GIVAUDAN TO ACQUIRE PORTFOLIO OF MAJOR COSMETIC INGREDIENTS FROM AMYRIS AND TO ESTABLISH STRATEGIC PARTNERSHIP FOR NATURAL, SUSTAINABLY SOURCED INGREDIENTS FOR THE BEAUTY INDUSTRY	PR